Cost-effectiveness of statins.
The efficacy of lipid-lowering with statins has become clear. Indirect estimations, and direct measurements from long-term randomized trials have also demonstrated cost-effectiveness, both in secondary and primary prevention of coronary heart disease. Targeting care efficiently to high-risk groups by calculating absolute risk is essential. However, it is clear that what would normally be very cost-effective interventions will put substantial strain on health care resources because of the common nature of coronary disease and risk factors.
Reckless
J P
JP
Department of Endocrinology, Diabetes & Metabolism, Royal United Hospital, Bath, UK. mpsjpdr@bath.ac.uk
D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D006801:Humans; D000960:Hypolipidemic Agents / Q000191:economics* / Q000627:therapeutic use*; D012307:Risk Factors; D006113:United Kingdom
D000960:Hypolipidemic Agents